Abstract
Gene and immunotherapeutic approaches to treat human malignant tumors are reviewed. Special attention is given to the different strategies of cancer gene therapy and to recent aspects of cytokine-supported tumor immunotherapy or tumor-specific vaccination. The limitations of these therapy approaches are critically discussed especially with respect to immune escape mechanisms.
Article PDF
Similar content being viewed by others
References
Sobol RE, Scanlon KJ (eds).The Internet Book of Gene Therapy. Appleton & Lange: Stamford, CT 1998.
Anderson WF. Human gene therapy.Nature 1998;392: 25–30.
Gage FH. Cell therapy.Nature 1998;392: 18–24.
Gewirtz AM. The c-myb proto-oncogene: a novel target for human gene therapy.Cancer Treat Res 1996;84: 93–112.
Nielsen LL, Maneval DC. p53 tumoursuppressor gene therapy for cancer.Cancer Gene Ther 1998;5: 52–63.
Wiechen K, Zimmer C, Dietel M. Selection of high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein.Cancer Gene Ther 1998;5: 45–51.
Schuler Met al. A phase I study of adenovirus mediated wild type p53 gene transfer in patients with advanced non-small cell lung cancer.Hum Gene Ther 1998;9: 2075–2082.
Rosolen Aet al. In vitro andin vivo antitumour effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma.Gene Ther 1998;5: 113–120.
Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies.J Natl Cancer Inst 1998;90: 370–380.
Dunbar CEet al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.Blood 1995;85: 3048–3057.
Goncalves F, Dubart A, Lacout C, Vainchenker W, Dumenil D. Stromal cells maintain the radioprotective capacity of CFU-S during retroviral infection.Gene Ther 1996;3: 761–768.
Roth C, Rochlitz CF, Kourilsky P. Immune response against tumours.Adv Immunol 1994;57: 281–351.
Viret C, Lindemann A. Tumour immunotherapy by vaccination with cytokine gene transfected cells.Intern Rev Immunol 1997;14: 193–212.
Panelli MC, Marincola FM. Immunotherapy update: From interleukin-2 to antigen-specific therapy. In: Perry MC (ed).ASCO Educational Book, American Society of Clinical Oncology 34th Annual Meeting, 1998; pp 467–473.
de Kernion JB, Sarna G, Figlin R, Lindner A, Smith RB. The treatment of renal cell carcinoma with human leukocyte alpha-interferon.J Urol 1983;130: 1063–1066.
Bindon Cet al. Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects.Br J Cancer 1983;47: 123–133.
Colombo MP, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumour rejection and systemic immunity through granulocyte T-lymphocyte cross-talk.Cancer Res 1992;52: 4853–4857.
Bubenik Jet al. Local administration of cells containing aninserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice.Immunol Lett 1988;19: 279–282.
Fearon ERet al. Interleukin-2 production by tumour cells bypasses T helper function in the generation of an antitumour response.Cell 1990;60: 397–403.
Gansbacher Bet al. Interleukin 2 gene transfer into tumour cells abrogates tumourigenicity and induces protective immunity.J Exp Med 1990;172: 1217–1224.
Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard EL. Interleukin 2-dependent activation of tumour-specific cytotoxic T lymphocytesin vivo.Eur J Immunol 1991;21: 851–854.
Allione Aet al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumour necrosis factoralpha, granulocyte-macrophage colony-stimulating factor, and gammainterferon gene or admixed with conventional adjuvants.Cancer Res 1994;54: 6022–6026.
Rosenthal FM, Zier KS, Gansbacher B. Human tumour vaccines and genetic engineering of tumours with cytokine and histocompatibility genes to enhance immunogenicity.Curr Opin Oncol 1994;6: 611–615.
Mertelsmann Ret al. Pilot study for the evaluation of T-cell-mediated tumour immunotherapy by cytokine gene transfer in patients with malignant tumours.J Mol Med 1995;73: 205–206.
Stoppacciaro Aet al. Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines.Eur J Immunol 1997;27: 2375–2382.
Cayeux Set al. Lack of correlation between rejection of tumour cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.Eur J Immunol 1997;27: 1657–1662.
van Elsas Aet al. Transfection of IL-2 augments CTL response to human melanoma cellsin vitro: immunological characterization of a melanoma vaccine.J Immunother 1997;20: 343–353.
Schmidt Wet al. Cancer vaccines: the interleukin 2 dosage effect.Proc Natl Acad Sci USA 1995;92: 4711–4714.
Sobol REet al. Injection of colon carcinoma patients with autologous irradiated tumour cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a phase I study.Hum Gene Ther 1995;6: 195–204.
Zier KS, Gansbacher B. IL-2 gene therapy of solid tumours: an approach for the prevention of signal transduction defects in T cells.J Mol Med 1996;74: 127–134.
Arienti Fet al. Limited antitumour T cell response in melanoma patients vaccinated with interleukin-2 genetransduced allogeneic melanoma cells.Hum Gene Ther 1996;7: 1955–1963.
Mackensen Aet al. Induction of tumour-specific cytotoxic T lymphocytes by immunization with autologous tumour cells and interleukin-2 gene transfected fibroblasts.J Mol Med 1997;75: 290–296.
Rochlitz CFet al. Gene therapy study of cytokine-transfected xenogenic cells (Vero-IL2) in patients with metastatic solid tumours.Cancer Gene Ther 1999;6 (sn3) (in press).
Cavallo Fet al. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.J Immunol 1992;149: 3627–3635.
Hock Het al. Mechanisms of rejection induced by tumour cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumour necrosis factor, or interferon gamma.Proc Natl Acad Sci USA 1993;90: 2774–2778.
Emtage PC, Wan Y, Bramson JL, Graham FL, Gauldie J. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumour regression in a murine breast adenocarcinoma model.J Immunol 1998;160: 2531–2538.
DeSilva DR, Feeser WS, Tancula EJ, Scherle PA. Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signalling pathways.J Exp Med 1996;183: 2017–2023.
Roth Cet al. Inhibition of tumour growth by histoincompatible cells expressing interleukin-2.Int Immunol 1992;4: 1429–1436.
Ikeda Het al. Characterization of anantigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.Immunity 1997;6: 199–208.
Paul Pet al. HLA-G expression in melanoma: a way for tumour cells to escape from immunosurveillance.Proc Natl Acad Sci USA 1998;95: 4510–4515.
Lode HNet al. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy.Blood 1998;91: 1706–1715.
Quintin-Colonna Fet al. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoural administration of histoicompatible cells expressing human interleukin-2.Gene Ther 1996;3: 1104–1112.
Cohen Ret al. Approaches to anti-tumour immunotherapy in mouse and humans. In: Gachelin G, Yikawa Y. Ishii S, Kourilsky P, Yaniv M (eds).Genes for development cell growth and infectious diseases. John Libbey Eurotext: Paris, 1995; pp 227–236.
Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumour activityin vivo.Cell 1989:57: 503–512.
Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumour effect of interleukin-4.Science 1992;257: 548–551.
Porgador Aet al. Interleukin-6 gene transfection into Lewis lung carcinoma tumour cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.Cancer Res 1992;52: 3679–3686.
Connor Jet al. Regression of bladder tumours in mice treated with interleukin-2 gene-modified tumour cells.J Exp Med 1993;177: 1127–1134.
Dranoff Get al. Vaccination with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumour immunity.Proc Natl Acad Sci USA 1993;90: 3539–3543.
Tahara H, Lotze MT. Antitumour effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.Gene Ther 1995;2: 96–106.
Zinkernagel RM, Doherty PC. Restriction ofin vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.Nature 1974;248: 701–702.
Townsend ARet al. The epitopes of influenza nucleoprotein recognized by cytotoxic T-lymphocytes can be defined with short synthetic peptides.Cell 1986;44: 959–968.
Traversari Cet al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumour antigen MZ2-E.J Exp Med 1992;176: 1453–1457.
Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens.Immunol Today 1997;18: 175–182.
Boon T, Coulie PG, Van den Eynde B. Tumour antigens recognized by T cells.Immunol Today 1997;18: 267–268.
Cox ALet al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.Science 1994;264: 716–719.
Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins.J Exp Med 1991;173: 273–276.
Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumour antigens.Curr Opin Immunol 1997;9: 709–716.
Jäger Eet al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.J Exp Med 1998;187: 265–270.
Skipper I, Stauss HJ. Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein.J Exp Med 1993;117: 1493–1498.
Wölfel Tet al. Ap16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.Science 1995;269: 1281–1284.
Ressing MEet al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified throughin vivo andin vitro immunogenicity studies of HLA-A0201-binding peptides.J Immunol 1995;154: 5934–5943.
De Plaen Eet al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family.Immunogenetics 1994;40: 360–369.
Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis.Cancer Res 1995;55: 3478–3482.
Lethé B, van der Bruggen P, Brasseur F, Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific CTL.Melanoma Res 1997;7: (Suppl. 2) S83-S88.
Fisk B, Blevins TL, Wharton JT. Ioannides CG Identification of an immunodominant peptide of HER-2/neu proto oncogene recognized by ovarian tumour-specific cytotoxic T lymphocyte lines.J Exp Med 1995;181: 2109–2117.
Van den Eynde BJ, van der Bruggen P. T cell defined tumour antigens.Curr Opin Immunol 1997;9: 684–693.
Robbins PFet al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumour infiltrating lymphocytes.J Exp Med 1996;183: 1185–1192.
Rubinfeld Bet al. Stabilization of beta-catenin by genetic defects in melanoma cell lines.Science 1997;275: 1790–1792.
Mukherji Bet al. Induction of antigen-specific cytolytic T cellsin situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.Proc Nat Acad Sci USA 1995;92: 8078–8082.
Rivoltini Let al. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in downregulating anti-tumour T-cell reactivity.Crit Rev Immunol 1998;18: 55–63.
Tjandrawan Tet al. Autologous human dendriphages pulsed with synthetic or natural tumour peptides elicit tumour-specific CTLsin vitro.J Immunother 1998;21: 149–157.
Uyttenhove Cet al. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumour antigen.Int J Cancer 1997;70: 349–356.
Nestle FOet al. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells.Nat Med 1998;4: 328–332.
Rosenberg SAet al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.Nat Med 1998;4: 321–327.
Castelli Cet al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes.J Exp Med 1995;181: 363–368.
Jäger Eet al. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals.Melanoma Res 1996;6: 419–425.
Romero Pet al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.J Immunol 1997:159: 2366–2374.
Kittlesen DJet al. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumour vaccine development.J. Immunol 1998;160: 2099–2106.
Anichini Aet al. Melanoma cells and normal melano-cytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.J Exp Med 1993;177: 989–998.
Bodmer JGet al. Nomenclature for factors of the HLA System, 1996.Hum Immunol 1997;53: 98–128.
Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.Cancer Res 1996;56: 4749–4757.
Scheibenbogen Cet al. Analysis of the T cell response to tumour and viral peptide antigens by an IFNgamma-ELISPOT assay.Int J Cancer 1997;71: 932–936.
Hu Xet al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.Cancer Res 1996;56: 2479–2483.
Jäger Eet al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.Int J Cancer 1997:71: 142–147.
Guo Yet al. Effective tumour vaccine generated by fusion of hepatoma cells with activated B cells.Science 1994;263: 518–520.
Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumour activity by immunization with fusions of dendritic and carcinoma cells.Nat Med 1997;3: 558–561.
Stuhler G, Walden P. Recruitment of helper T cells for induction of tumour rejection by cytolytic T lymphocytes.Cancer Immunol Immunother 1994;39: 342–345.
Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells.Curr Opin Immunol 1997;9: 10–16.
Topalian SLet al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.J Exp Med 1996;183; 1965–1971.
Yee Cet al. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients followingin vitro stimulation with recombinant vaccinia virus.J Immunol 1996;157: 4079–4086.
Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.J Exp Med 1983;157: 1040–1052.
Marincola FMet al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.J Immunol 1994;153: 1225–1237.
Restifo NPet al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.J Natl Cancer Inst 1996;88: 100–108.
Seliger Bet al. Down-regulation of the MHC class I antigen-processing machinery after transformation of murine fibroblasts.Eur J Immunol 1998;28: 122–133.
Seliger Bet al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.Cancer Res 1996;56: 1756–1760.
Elliott BE, Carlow DA, Rodricks AM, Wade A. Perspectives on the role of MHC antigens in normal and malignant cell development.Adv Cancer Res 1989;53: 181–245.
Wang Z, Margulies L, Hicklin DJ, Ferrone S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression.Tissue Antigens 1996;47: 382–390.
Restifo NPet al. Identification of human cancers deficient in antigen processing.J Exp Med 1993;177: 265–272.
Seliger B, Maeurer MJ, Ferrone S. TAP off-tumours on.Immunol Today 1997;18: 292–299.
Chen Let al. Costimulation of antitumour immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4.Cell 1992;71: 1093–1102.
Townsend SE, Allison JP. Tumour rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.Science 1993;259: 368–370.
Trojan Jet al. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA.Science 1993;259: 94–97.
Wortzel RD, Philipps C, Schreiber H. Multiple tumour-specific antigens expressed on a single tumour cell.Nature 1983;304: 165–167.
Morrison LA, Lukacher AE, Braciale VL, Fan DP, Braciale TJ. Differences in antigen presentation to MHC class I and II-restricted Influenza virus-specific cytolytic T lymphocyte clones.J Exp Med 1986;163: 903–921.
Braciale TJet al. Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes.Immunol Rev 1987;98: 95–114.
Bjorkman PJet al. The foreign antigen-binding site and T-cell recognition regions of class I histocompatibility antigens.Nature 1987;329: 512–518.
Ostrand-Rosenberg S, Clements VK, Thakur A, Cole GA. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection.J Immunogenet 1989;16: 343–349.
Becker JC, Brocker EB. Lymphocyte-melanoma interaction: role of surface molecules.Recent Results Cancer Res 1995;139: 205–214.
Maeurer MJet al. Tumour escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of the immunodominant MART-1/Malan-A antigen.J Clin Invest 1996;98: 1633–1641.
Hicklin DJet al. Beta 2-microglobulin gene mutations for immune surveillance.Melanoma Res 1997;7 (Suppl.): 67–74.
Armstrong TD, Clements VK, Ostrand-Rosenberg S. MHC class II-transfected tumour cells directly present antigen to tumour-specific CD4+ T lymphocytes.J Immunol 1998;160: 661–666.
Sheperd JCet al. TAP1-dependent peptide translocationin vitro is ATP-dependent and peptide-selective.Cell 1993;74: 577–584.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jantscheff, P., Herrmann, R. & Rochlitz, C. Cancer gene and immunotherapy: recent developments. Med Oncol 16, 78–85 (1999). https://doi.org/10.1007/BF02785840
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02785840